Puriblood Medical Valuation

Q: What is the Fair Price of 6847 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6847 (NT$94.4) is trading above our estimate of [[fair value]] (NT$53.07)

Is 6847 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6847 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6847 (NT$94.4) is trading above our estimate of fair value (NT$53.07)

Significantly Below Fair Value: 6847 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6847?

Key metric: As 6847 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6847. This is calculated by dividing 6847's market cap by their current revenue.
What is 6847's PS Ratio?
PS Ratio	10.3x
Sales	NT$126.56m
Market Cap	NT$1.30b

6847 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.9x
Enterprise Value/EBITDA	-34.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6847's PS Ratio compare to its peers?

The above table shows the PS ratio for 6847 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.6x
6767 Wiltrom	3x	n/a	NT$947.5m
6730 Lagis Enterprise	2.6x	n/a	NT$1.2b
4744 CVC Technologies	0.9x	n/a	NT$1.1b
6572 PlexBio	12.2x	n/a	NT$1.3b
6847 Puriblood Medical	10.6x	n/a	NT$1.3b

Price-To-Sales vs Peers: 6847 is expensive based on its Price-To-Sales Ratio (10.6x) compared to the peer average (4.6x).

Price to Sales Ratio vs Industry

How does 6847's PS Ratio compare vs other companies in the TW Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
4116 BenQ Medical Technology	0.5x	n/a	US$65.56m
4121 Rossmax International	0.4x	n/a	US$45.39m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6847 is expensive based on its Price-To-Sales Ratio (10.6x) compared to the TW Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 6847's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6847 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6847's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.3b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

1.9%

-27.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

0.4%

2.6%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

-0.3%

6.0%